Skip to main content
SpringerLink
Log in

Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin

  • Review
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Use of dipeptidyl peptidase-4 (DPP-4) inhibitors is prevalent for the treatment of type 2 diabetes since they have fewer adverse effects compared with other non-insulin medications currently available; however, as monotherapy, the glycosylated hemoglobin (HbA1c)-lowering power of these agents is moderate. The aim of this article is to evaluate the current literature regarding the safety and efficacy of DPP-4 inhibitors in combination with metformin.

Methods

A literature search was conducted through MEDLINE (from 1950 to October 2012), PubMed (from 1966 to October 2012), EMBASE (from 1966 to October 2012), and International Pharmaceutical Abstracts (from 1970 to October 2012) using the search terms “sitagliptin,” “linagliptin,” “alogliptin,” “vildagliptin,” “saxagliptin,” and “metformin.” Studies that did not evaluate the DPP-4 inhibitors in combination with metformin and those that were not phase 3, were excluded.

Results

Many of the studies evaluated DPP-4 inhibitors in combination with metformin versus glucagon-like peptide-1 (GLP-1) agonists, placebo, DPP-4 inhibitors as monotherapy, thiazolidinediones, and sulfonylureas. The results of these noninferiority trials were that DPP-4 inhibitors as a whole are noninferior to either each other or other agents except for GLP-1 agonists. Also, in superiority studies, GLP-1 agonists proved to have greater HbA1c lowering.

Conclusion

In summary, DPP-4 inhibitors play a vital role in the treatment of diabetes. They have relatively limited adverse effects, especially regarding hypoglycemia. DPP-4 inhibitors in combination with metformin are generally well tolerated and are available as combination products to reduce pill burden and enhance compliance. The limitations to DPP-4 inhibitors are the lack of outcomes data and more limited HbA1c lowering than other medications currently approved for the treatment of type 2 diabetes. However, as previously stated, thiazolidinediones, glinides, sulfonylureas, pramlinitide, and GLP-1 agonists are all quite beneficial in HbA1c lowering but are not without major adverse effects. Therefore, DPP-4 inhibitors have a vital role as an oral add-on agent for the treatment of type 2 diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Januvia [package insert]. Northumberland, United Kingdom: Merck & Co., Inc.

  2. Onglyza [package insert]. Princeton, New Jersey: Bristol-Myers Squibb; December 2011.

  3. Tradjenta [package insert]. Ridgefield, Connecticut: Boehringer Ingelheim Pharmaceuticals, Inc; September 2012.

  4. Nesina [package insert]. Deerfield, Illinois: Takeda Pharmaceuticals America, Inc; January 2013.

  5. Galvus [prescribing information]. Nurenberg, Germany: Novartis Pharmaceuticals.

  6. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical Management of Hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. Diabetes Care. 2009;32:193–203.

    Article  PubMed  CAS  Google Scholar 

  7. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endoc Pract. 2009;15:540–559.

    Article  Google Scholar 

  8. Inzucchi SE, Bergenstal RM, Buse JB, et al; American Diabetes Association; European Association for Study of Diabetes. Management of hyperglycemia in type 2 diabetes: A patient centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;25:1364–1379.

    Article  Google Scholar 

  9. CONSORT. CONSORT 2010 checklist of information to include when reporting a randomized trial. Available at: http://www.consort-statement.org/consort-statement/. Accessed Jan 15 2013.

  10. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG. Reporting of noninferiority and equivalence randomized trials extension of the CONSORT 2010 statement. JAMA. 2012;308:2594–2604.

    Article  PubMed  CAS  Google Scholar 

  11. Wainstein J, Katz L, Engel SS, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab. 2012;14:409–418.

    Article  PubMed  CAS  Google Scholar 

  12. Arechavaleta R, Seck T, Chen Y, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011;13:160–168.

    Article  PubMed  CAS  Google Scholar 

  13. Pratley R, Nauck M, Bailey T, et al; 1860-LIRADPP-4 Study Group. One year liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomized, parallel-group, open-label trial. Int J Clin Pract. 2011;65:397–407.

    Article  PubMed  CAS  Google Scholar 

  14. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26:540–549.

    Article  PubMed  CAS  Google Scholar 

  15. Bergenstal RM, Wysham C, MacConell L, et al; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. Lancet. 2010;376:431–439.

    Article  PubMed  Google Scholar 

  16. Scott R, Loeys T, Davies MJ, Engel SS. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008;10:959–969.

    Article  PubMed  CAS  Google Scholar 

  17. Gallwitz B, Rosenstock J, Rauch T, et al. 2-Year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomized, double-blind, non-inferiority trial. Lancet. 2012;380:475–483.

    Article  PubMed  CAS  Google Scholar 

  18. Haak T, Meinicke T, Jones R, Weber S, Eynatten M, Woerle Hj. Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2012;14:565–574.

    Article  PubMed  CAS  Google Scholar 

  19. Taskinen MR, Rosenstock J, Tamminen I, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011;13:65–74.

    Article  PubMed  CAS  Google Scholar 

  20. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010;27:318–326.

    Article  PubMed  CAS  Google Scholar 

  21. Blonde L, Dagogo-Jack S, Banerji MA, et al. Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIANT trial — a primary care, type 2 diabetes study. Diabetes Obes Metab. 2009;11:978–986.

    Article  PubMed  CAS  Google Scholar 

  22. Ferrannini E, Fonseca V, Zinman B, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009;11:157–166.

    Article  PubMed  CAS  Google Scholar 

  23. Goke B, Gallwitz B, Eriksson J, Hellqvist A, Nilsson-Gause I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52 week randomized controlled trial. Int J Clin Pract. 2010;64:1619–1631.

    Article  PubMed  CAS  Google Scholar 

  24. Defronzo RA, Hissa MN, Garber AJ, et al; Saxagliptin 014 Study Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009;32:1649–1655.

    Article  PubMed  CAS  Google Scholar 

  25. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy; a multicentre, randomized, double-blind, placebo-controlled study. Int J Clin Pract. 2009;63:46–55.

    Article  PubMed  CAS  Google Scholar 

  26. Takeda Pharmaceuticals. Takeda resubmits new drug applications to the United States Food and Drug Administration for alogliptin and the fixeddose combination alogliptin and pioglitazone. Available at: http://www.takeda.us/newsroom/press_release_detail.aspx?year=2012&id=244. Accessed Jan 22 2013.

  27. US Food and Drug Administration. FDA approves three new drug treatments for type 2 diabetes. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm336942.htm. Accessed Jan 28 2013.

  28. Merck. Putting patients first by addressing significant unmet medical needs: update on cardiovascular outcomes study with Januvia. Available at: http://www.merck.com/mrl/clinical_trials/outcomes_study.html. Accessed March 21 2013.

  29. ClinicalTrials.gov. Sitagliptin cardiovascular outcome study (0431-082 AM1) (TECOS). Available at: http://clinicaltrials.gov/ct2/show/NCT00790205?term=DPP+4+inhibitors&rank=132. Accessed March 21 2013.

  30. ClinicalTrials.gov. Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications (SAVOR-TIMI 53). Available at: http://clinicaltrials.gov/ct2/show/NCT01107886?term=saxagliptin&cond=%22Coronary+Artery+Disease%22&rank=2. Accessed March 21 2013.

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy Practice, Nova Southeastern University, College of Pharmacy, 3200 South University Drive, Ft. Lauderdale, Florida, 33328, USA

    Andrea D. Fass & Jennifer A. Gershman

Authors
  1. Andrea D. Fass
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jennifer A. Gershman
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea D. Fass.

Additional information

To view enhanced content go to www.advancesintherapy.com

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fass, A.D., Gershman, J.A. Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Combination with Metformin. Adv Therapy 30, 337–353 (2013). https://doi.org/10.1007/s12325-013-0023-6

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-013-0023-6

Keywords

Search

Navigation